Julian R Molina

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi request reprint Pralatrexate, a dihydrofolate reductase inhibitor for the potential treatment of several malignancies
    Julian R Molina
    Department of Oncology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    IDrugs 11:508-21. 2008
  2. pmc Can gene expression profiling predict survival for patients with squamous cell carcinoma of the lung?
    Zhifu Sun
    Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota 55905, USA
    Mol Cancer 3:35. 2004
  3. ncbi request reprint Predictors of survival from urachal cancer: a Mayo Clinic study of 49 cases
    Julian R Molina
    Mayo Clinic and Foundation, Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 110:2434-40. 2007
  4. ncbi request reprint Advances in chemotherapy of non-small cell lung cancer
    Julian R Molina
    Division of Medical Oncology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Chest 130:1211-9. 2006
  5. ncbi request reprint Primary salivary gland-type lung cancer: spectrum of clinical presentation, histopathologic and prognostic factors
    Julian R Molina
    Division of Medical Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Cancer 110:2253-9. 2007
  6. pmc Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship
    Julian R Molina
    Department of Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 83:584-94. 2008
  7. pmc Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data
    Julian R Molina
    Department of Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Clin Cancer Res 14:7900-8. 2008
  8. ncbi request reprint The Ras/Raf/MAPK pathway
    Julian R Molina
    Division of Medical Oncology Mayo Clinic, Rochester, MN 55905, USA
    J Thorac Oncol 1:7-9. 2006
  9. ncbi request reprint Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus
    Hongzhi Zou
    Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    Int J Cancer 116:584-91. 2005
  10. ncbi request reprint Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002
    Antonio L Visbal
    Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota 55905, USA
    Ann Thorac Surg 78:209-15; discussion 215. 2004

Detail Information

Publications36

  1. ncbi request reprint Pralatrexate, a dihydrofolate reductase inhibitor for the potential treatment of several malignancies
    Julian R Molina
    Department of Oncology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    IDrugs 11:508-21. 2008
    ..In contrast, for pralatrexate to be incorporated into the accepted treatment options for NSCLC, the drug will need to prove clear superiority to established agents...
  2. pmc Can gene expression profiling predict survival for patients with squamous cell carcinoma of the lung?
    Zhifu Sun
    Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota 55905, USA
    Mol Cancer 3:35. 2004
    ..We also evaluated the gene markers' accuracy in segregating samples to their respective group. Functional gene networks for the significant genes were retrieved, and their association with survival was tested...
  3. ncbi request reprint Predictors of survival from urachal cancer: a Mayo Clinic study of 49 cases
    Julian R Molina
    Mayo Clinic and Foundation, Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 110:2434-40. 2007
    ..Outcome results of a long-term analysis of urachal cancer using a new staging system are presented...
  4. ncbi request reprint Advances in chemotherapy of non-small cell lung cancer
    Julian R Molina
    Division of Medical Oncology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Chest 130:1211-9. 2006
    ....
  5. ncbi request reprint Primary salivary gland-type lung cancer: spectrum of clinical presentation, histopathologic and prognostic factors
    Julian R Molina
    Division of Medical Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Cancer 110:2253-9. 2007
    ..The clinicopathologic profiles, symptoms on presentation, and long-term outcomes of patients with ACC and MEC as an overall group have not been defined recently...
  6. pmc Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship
    Julian R Molina
    Department of Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 83:584-94. 2008
    ....
  7. pmc Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data
    Julian R Molina
    Department of Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Clin Cancer Res 14:7900-8. 2008
    ..The present studies were done to determine the effect of combining topotecan and the dual epidermal growth factor receptor/HER2 inhibitor lapatinib in tissue culture, a murine xenograft model, and a phase I clinical trial...
  8. ncbi request reprint The Ras/Raf/MAPK pathway
    Julian R Molina
    Division of Medical Oncology Mayo Clinic, Rochester, MN 55905, USA
    J Thorac Oncol 1:7-9. 2006
  9. ncbi request reprint Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus
    Hongzhi Zou
    Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    Int J Cancer 116:584-91. 2005
    ..Aberrant promoter methylation appears to functionally silence SFRP gene expression in esophageal adenocarcinoma...
  10. ncbi request reprint Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002
    Antonio L Visbal
    Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota 55905, USA
    Ann Thorac Surg 78:209-15; discussion 215. 2004
    ..Most of the reports are limited to selected groups of patients. The magnitude of gender effect on NSCLC survival across disease stage, tumor histology, and therapies needs to be further characterized...
  11. pmc A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer
    Keith C Bible
    Division of Medical Oncology, Mayo Clinic Rochester, Rochester, Minnesota 55905, USA
    J Clin Endocrinol Metab 97:3179-84. 2012
    ..Pazopanib, an inhibitor of kinases including vascular endothelial growth factor receptor, demonstrated impressive activity in progressive metastatic differentiated thyroid cancer, prompting its evaluation in anaplastic thyroid cancer (ATC)...
  12. pmc Effect of disrupting seven-in-absentia homolog 2 function on lung cancer cell growth
    Atique U Ahmed
    Departments of Surgery and Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Natl Cancer Inst 100:1606-29. 2008
    ..We examined whether inhibiting SIAH-2 function blocks lung cancer growth...
  13. ncbi request reprint Aberrant methylation of the eyes absent 4 gene in ulcerative colitis-associated dysplasia
    Neal K Osborn
    Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Clin Gastroenterol Hepatol 4:212-8. 2006
    ..This study explored the eyes absent 4 (EYA4) gene promoter methylation in noncolitic colorectal tissues and assessed its discrimination for neoplasia in chronic ulcerative colitis (CUC)...
  14. ncbi request reprint Development of a multidisciplinary, multicampus subspecialty practice in endocrine cancers
    Keith C Bible
    Mayo Clinic, Rochester, MN 55905, USA
    Am J Manag Care 18:e162-7. 2012
    ..We therefore sought to build interest in endocrine cancers, improve physician experience, and develop innovative approaches to treating patients with these neoplasms...
  15. pmc Do patients with schizophrenia receive state-of-the-art lung cancer therapy? A brief report
    Farrah J Mateen
    Department of Neurology, Mayo Clinic, Rochester, MN, USA
    Psychooncology 17:721-5. 2008
    ..Patients with schizophrenia sometimes receive substandard medical care. This study explored such disparities among lung cancer patients with underlying schizophrenia...
  16. pmc Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials
    Nathan R Foster
    Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota
    Cancer 117:1262-71. 2011
    ....
  17. ncbi request reprint A Phase II NCCTG study of irinotecan and docetaxel in previously treated patients with non-small cell lung cancer
    Julian R Molina
    Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Cancer Invest 24:382-9. 2006
    ..This Phase II study was undertaken to define the efficacy and toxicity of the combination of docetaxel and irinotecan for the second-line treatment of non-small cell lung cancer (NSCLC)...
  18. ncbi request reprint Phase II NCCTG trial of oral topotecan and paclitaxel with G-CSF (filgrastim) support in patients with previously untreated extensive-stage small cell lung cancer
    Julian R Molina
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Am J Clin Oncol 29:246-51. 2006
    ..To determine the efficacy and toxicity of oral topotecan and paclitaxel in untreated patients with extensive stage small cell lung cancer (SCLC)...
  19. ncbi request reprint Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors
    Paul Haluska
    Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Clin Cancer Res 13:5834-40. 2007
    ..This phase I study was undertaken to define the maximum tolerated dose, safety, and pharmacokinetic profile of CP-751,871...
  20. doi request reprint Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy
    Robert L Foote
    Endocrine Malignancies Disease Oriented Group, Mayo Clinic Comprehensive Cancer Center, Rochester, Minnesota, USA
    Thyroid 21:25-30. 2011
    ....
  21. doi request reprint Phase I dose escalation study of the PKCĪ¹ inhibitor aurothiomalate for advanced non-small-cell lung cancer, ovarian cancer, and pancreatic cancer
    Aaron S Mansfield
    aDepartment of Medical Oncology, Mayo Clinic, Rochester, Minnesota bDepartment of Cancer Biology, Mayo Clinic, Jacksonville, Florida cDepartment of Internal Medicine, Greater Baltimore Medical Center, Baltimore, Maryland dDepartment of Medicine, Roswell Park Cancer Institute, Buffalo, New York, USA
    Anticancer Drugs 24:1079-83. 2013
    ..In summary, this phase I study was successful in identifying ATM 50 mg intramuscularly weekly as the MTD. Future clinical investigations targeting PKCĪ¹ are currently in progress...
  22. ncbi request reprint A phase I and pharmacokinetic study of the selective, non-peptidic inhibitor of matrix metalloproteinase BAY 12-9566 in combination with etoposide and carboplatin
    Julian R Molina
    Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Anticancer Drugs 16:997-1002. 2005
    ..However, the combination of BAY, VP-16 and CDBCA produces significant hematologic toxicity. Findings from this study may help to direct further studies with other inhibitors of MMPs...
  23. pmc FAVL elevation in human tumors disrupts Fanconi anemia pathway signaling and promotes genomic instability and tumor growth
    Jun Zhang
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Clin Invest 120:1524-34. 2010
    ..We further believe that these data will prove useful for developing additional tools for fighting human cancer...
  24. pmc Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study
    Keith C Bible
    Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA
    Lancet Oncol 11:962-72. 2010
    ..We investigated the safety and efficacy of pazopanib...
  25. ncbi request reprint The role of Pemetrexed (Alimta , LY231514) in lung cancer therapy
    Julian R Molina
    Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA
    Clin Lung Cancer 5:21-7. 2003
    ..In this review, the pharmacology and clinical activity of pemetrexed in NSCLC cancer is discussed...
  26. ncbi request reprint Ectopic expression of VAV1 reveals an unexpected role in pancreatic cancer tumorigenesis
    Martin E Fernandez-Zapico
    Gastroenterology Research Unit, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Cancer Cell 7:39-49. 2005
    ..Thus, the discovery of prooncogenic pathways regulated by Vav1 makes it an attractive target for therapeutic intervention...
  27. pmc 53BP1 cooperates with p53 and functions as a haploinsufficient tumor suppressor in mice
    Irene M Ward
    Division of Oncology Research, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Mol Cell Biol 25:10079-86. 2005
    ..We conclude that 53BP1 functions as a dosage-dependent caretaker that promotes genomic stability by a mechanism that preserves chromosome structure and number...
  28. ncbi request reprint Chemotherapy-induced ovarian failure: manifestations and management
    Julian R Molina
    Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Drug Saf 28:401-16. 2005
    ....
  29. pmc Ranibizumab combined with low-dose sorafenib for exudative age-related macular degeneration
    Teresa Diago
    Department of Ophthalmology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 83:231-4. 2008
    ..Randomized trials of adding sorafenib to standard therapy for patients with neovascular AMD should be considered...
  30. doi request reprint Concurrent MCL1 and JUN amplification in pseudomyxoma peritonei: a comprehensive genetic profiling and survival analysis
    Terence T Sio
    Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA
    J Hum Genet 59:124-8. 2014
    ..Expression of MCL1 may not be completely dependent on amplification. The prognostic and therapeutic implications of these recurrent mutational events are the subject of ongoing investigation. ..
  31. doi request reprint Adjuvant chemoradiation therapy with high-dose versus weekly cisplatin for resected, locally-advanced HPV/p16-positive and negative head and neck squamous cell carcinoma
    Jessica L Geiger
    Department of Internal Medicine, Mayo Clinic, Rochester, MN, United States
    Oral Oncol 50:311-8. 2014
    ..This study compares the outcomes of patients with locally-advanced HPV-negative HNSCC and HPV/p16-positive oropharynx HNSCC treated with adjuvant chemoradiation therapy with either high-dose or weekly cisplatin...
  32. ncbi request reprint Frequent methylation of eyes absent 4 gene in Barrett's esophagus and esophageal adenocarcinoma
    Hongzhi Zou
    Department of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA
    Cancer Epidemiol Biomarkers Prev 14:830-4. 2005
    ....
  33. pmc Salivary gland-type lung carcinomas: an EGFR immunohistochemical, molecular genetic, and mutational analysis study
    Ricardo S Macarenco
    CIPAX, Medicina Diagnostica, Sao Jose dos Campos, Sao Paulo, Brazil
    Mod Pathol 21:1168-75. 2008
    ..Immunoexpression of epidermal growth factor receptor in salivary gland-type lung carcinomas is not related to epidermal growth factor receptor gene copy number or mutational status...
  34. pmc Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers
    Alex A Adjei
    Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    J Clin Oncol 26:2139-46. 2008
    ..To assess the tolerability, pharmacokinetics (PKs), and pharmacodynamics (PDs) of the mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancer...
  35. ncbi request reprint Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer
    Alex A Adjei
    Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Clin Cancer Res 13:2684-91. 2007
    ..To evaluate the combination of sorafenib and gefitinib in patients with advanced non-small cell lung cancer...
  36. ncbi request reprint A comprehensive search for DNA amplification in lung cancer identifies inhibitors of apoptosis cIAP1 and cIAP2 as candidate oncogenes
    Zunyan Dai
    Program of Human Cancer Genetics, Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, OH, 43210, USA
    Hum Mol Genet 12:791-801. 2003
    ..Immunohistochemistry and western blot analysis identified cIAP1 and cIAP2 as potential oncogenes in this region as both are overexpressed in multiple lung cancers with or without higher copy numbers...